- Home
- UMAC vs ALT Comparison
UMAC vs ALT Comparison
Compare UMAC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UMAC | ALT |
|---|---|---|
| Founded | 2019 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.2M | 421.5M |
| IPO Year | 2023 | 2005 |
Fundamental Metrics
Financial Performance| Metric | UMAC | ALT |
|---|---|---|
| Price | $15.91 | $3.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $20.00 | $17.67 |
| AVG Volume (30 Days) | ★ 4.6M | 2.5M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.73 | 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,199,217.00 | $41,000.00 |
| Revenue This Year | $115.39 | N/A |
| Revenue Next Year | $101.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 101.23 | ★ 105.00 |
| 52 Week Low | $4.67 | $2.87 |
| 52 Week High | $23.38 | $7.73 |
Technical Indicators
Market Signals| Indicator | UMAC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 55.93 | 51.91 |
| Support Level | $8.40 | $3.40 |
| Resistance Level | $16.52 | $3.54 |
| Average True Range (ATR) | 1.45 | 0.17 |
| MACD | 0.27 | 0.07 |
| Stochastic Oscillator | 94.41 | 96.32 |
Price Performance
Historical ComparisonAbout UMAC Unusual Machines Inc.
Unusual Machines Inc is engaged in manufactures and sells drone components and drones across a diversified brand portfolio through business-to-business (B2B) sales and a curated retail channel.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.